Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Airway Response Clinical Trial

Official title:

Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01371968
• Other study ID #: Alfentanil LMA
• Status: Completed
• Phase: N/A
• First received: May 4, 2011
• Last updated: October 25, 2017
• Start date: February 2011
• Est. completion date: November 2011

Study information

• Verified date: October 2017
• Source: University of Malaya
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Description:

The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids

The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. ASA I and II patients

2. Age 18 to 49 years old

3. Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids.

Exclusion Criteria:

1. Potential difficult airway

2. Reactive airway disease or sign and symptoms of upper respiratory tract infection.

3. History of cardiac, pulmonary and renal diseases

4. Body Mass Index > 30 kgm2.

5. Risk of aspiration.

6. Poor dentition with high risk of damage.

7. Patient refusal.

Related Conditions & MeSH terms

• Airway Response

Intervention

Drug:
• alfentanil
Alfentanil is administered intravenously at the end of surgery.

Locations

Country	Name	City	State
Malaysia	University Malaya Medical Centre	Kuala Lumpur

Sponsors (2)

Lead Sponsor	Collaborator
University of Malaya	Malaysian Society of Anaesthesiologists

Country where clinical trial is conducted

Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults		6 months
Secondary	Number of patient with airway complication		after administration of alfentanil and within 1 min of LMA removal